Experimental Alzheimer’s drug shows promise against brain plaques
An experimental drug called aducanumab dramatically reduced the toxic plaques found in the brains of people living with Alzheimer’s disease, according to results of a Phase1b clinical trial designed to test safety and tolerability rather than effectiveness. The results, previously reported at the Alzheimer’s Association International Conference® 2015 (AAIC®), hinted that the drug may also be able to slow the loss of memory and thinking. Experts caution that additional, larger studies will be necessary to determine if aducanumab has an effect on slowing down Alzheimer’s.
http://www.optimumseniorcare.com/services/alzheimerscare.php